Lying at the intersection between neurobiology and epigenetics, Rett syndrome (RTT) has garnered intense interest in recent years, not only from a broad range of academic scientists, but also from the pharmaceutical and biotechnology industries. In addition to the critical need for treatments for this devastating disorder, optimism for developing RTT treatments derives from a unique convergence of factors, including a known monogenic cause, reversibility of symptoms in preclinical models, a strong clinical research infrastructure highlighted by an NIH-funded natural history study and well-established clinics with significant patient populations. Here, we review recent advances in understanding the biology of RTT, particularly promising preclinical findings, lessons from past clinical trials, and critical elements of trial design for rare disorders.
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Progress in Identifying Potential RTT Therapeutics
RTT is a severe neurodevelopmental disorder resulting from mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MeCP2) [1] . Progress in understanding the pathophysiology of RTT and in identifying potential therapies has outpaced that in many other neurodevelopmental disorders due, in part, to the availability of rodent models with good construct and face validity [2] [3] [4] . These include strains of mice carrying either Mecp2-null or hypomorphic alleles or human disease-causing mutations [2, 4] , as well as an Mecp2-null rat model (SAGE Labs). In addition, some of the core symptoms of RTT, such as abnormal breathing, are more readily quantifiable and translate more directly from mice to humans compared with the complex behavioral abnormalities that define more prevalent disorders, such as nonsyndromic autism. Over the past few years, studies of the biology of MeCP2 (Box 1) and the consequences of MeCP2 loss for neural circuit function and behavior have led to the identification of potential therapeutic strategies [3] [4] [5] [6] [7] [8] , including: (i) molecular genetic approaches that target MECP2 itself, ranging from gene and protein replacement therapy to development of novel tools for activating the wild-type allele on the inactive X chromosome; (ii) pharmacologic approaches that target mechanisms downstream of MECP2 to restore excitatory-inhibitory synaptic balance in specific neural circuits, including some drugs that are now in early-stage clinical trials in patients with RTT (Figure 1 ; see Table S1 in the supplemental information online for the figure references).
Genetics and Clinical Features of RTT
The MECP2 gene is X linked and RTT mutations arise predominantly in the paternal germ line. Given that the gene is subject to X chromosome inactivation, most affected individuals are female heterozygotes who are somatic mosaics for normal and mutant MECP2. In rare cases,
Trends
Studies of RTT mouse models have convincingly demonstrated that neurological disability caused by loss of methyl-CpG-binding protein 2 (MeCP2) function is reversible to a significant degree.
Recent insights into the biology of MeCP2 and its role in regulating interactions between DNA and repressor protein complexes seemed poised to resolve longstanding controversies about the role of MeCP2 in transcriptional control.
The knowledge that reintroduction of Mecp2 can restore circuit functionality in mouse models of RTT has spurred the investigation of gene replacement and gene reactivation strategies as comprehensive and potentially transformative treatment approaches for RTT.
Pharmacologic strategies targeting neurotransmitter and neuronal growth factor signaling pathways have proven highly effective at improving neurological function in mouse models of RTT.
The natural history of RTT is becoming increasingly well defined, facilitating the identification of clinically measurable endpoints for therapeutic trials.
